Sanshimao formula inhibits the hypoxia-induced pro-angiogenesis of hepatocellular carcinoma cells partly through regulating MKK6/p38 signaling pathway

J Pharm Pharmacol. 2024 Apr 3;76(4):426-434. doi: 10.1093/jpp/rgad086.

Abstract

Objectives: Sanshimao (SSM) is a traditional Chinese medicine formula for advanced hepatocellular carcinoma (HCC). This study was designed to investigate the effect of SSM on HCC-induced angiogenesis and to explore the potential mechanism.

Methods: The endothelial cells were cultured with HCC cells conditioned medium in the 1% oxygen atmosphere to imitate tumor hypoxia microenvironment. EA.hy926 cells migration and tubulogenesis were detected by tube formation and scratch-wound assay. The protein microarray was employed to explore SSM-targeted proteins in Huh7 cells. We also established an animal model to observe the effects of SSM on angiogenesis in vivo.

Results: The data indicated that SSM reduced HCC-induced migration and tube formation of EA.hy926 cells at low dose under hypoxic conditions. These effects might be partly owing to suppression of HIF-1α-induced vascular endothelial growth factorα expression in Huh7 cells. Moreover, this inhibition was in an MKK6/P38-dependent way. Besides, Huh7 subcutaneous tumor models in nude mice further demonstrated the inhibition of SSM on tumor weight might be exerted partly by reduction of angiogenesis via blocking MKK6/P38 signaling pathways.

Conclusion: SSM inhibits HCC-induced pro-angiogenesis under hypoxic conditions via suppression of MKK6/P38 signaling pathways, which is favorable for HCC tumor growth.

Keywords: HCC; MKK6/P38; SSM; hypoxia; pro-angiogenesis.

MeSH terms

  • Angiogenesis
  • Animals
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / metabolism
  • Cell Line, Tumor
  • Drugs, Chinese Herbal* / pharmacology
  • Endothelial Cells / metabolism
  • Hypoxia / drug therapy
  • Hypoxia / metabolism
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / metabolism
  • MAP Kinase Kinase 6 / drug effects
  • MAP Kinase Kinase 6 / metabolism
  • Mice
  • Mice, Nude
  • Neovascularization, Pathologic* / drug therapy
  • Neovascularization, Pathologic* / metabolism
  • Signal Transduction
  • Tumor Microenvironment
  • p38 Mitogen-Activated Protein Kinases / drug effects
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Drugs, Chinese Herbal
  • MAP2K6 protein, human
  • MAP Kinase Kinase 6
  • p38 Mitogen-Activated Protein Kinases